ANDA 76125, held by Sun Pharmaceutical Industries. Fluvoxamine Maleate.
As of Nov 21, 2026, ANDA 76125 (Fluvoxamine Maleate), held by Sun Pharmaceutical Industries, was first approved by FDA on Apr 29, 2002, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 29, 2002 | Original application | Approved | None posted |
| Fluvoxamine Maleate25MG · tablet;oral | Fluvoxamine Maleate | Discontinued |
| Fluvoxamine Maleate50MG · tablet;oral | Fluvoxamine Maleate | Discontinued |
| Fluvoxamine Maleate100MG · tablet;oral | Fluvoxamine Maleate | Discontinued |
| Aug 31, 2023 | Supplement 15Labeling · Standard review | Approved | None posted |
| Jun 27, 2007 | Supplement 14Labeling | Approved | None posted |
| May 12, 2007 | Supplement 13Labeling | Approved | None posted |
| Feb 21, 2007 | Supplement 12Labeling | Approved | None posted |
| Jul 24, 2006 | Supplement 11Labeling | Approved | None posted |
| Oct 20, 2004 | Supplement 4Labeling | Approved | None posted |
| Feb 13, 2004 | Supplement 3Labeling | Approved | None posted |
| Apr 29, 2002 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters